Faced by a majority of bullish analyst comments vs. one very negative and well publicized review by Smith Barney of Cephalon's Myotrophin for amyotrophic lateral sclerosis, investors dumped shares of CEPH and partner Chiron (CHIR) in anticipation of Friday's FDA advisory panel meeting on the drug.

CEPH shares closed the week at $23.125, down $3.875 (14 percent) on big volume of 8.8 million shares. CHIR skidded $8 (8 percent) to close at $97. Neither stock traded on Friday.